Sologen Tablet (Methylprednisolone)

Adult dosage

1. The initial dose may vary from 4mg to 48mg of methylprednisolone per day, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, although a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If satisfactory clinical results are not obtained after a reasonable period, discontinue treatment and switch to another appropriate therapy. The dose must be determined individually according to the disease being treated and the patient's response. After an adequate response is obtained, determine the appropriate maintenance dose by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Continuous monitoring of the dose is required. Situations that may require dose adjustment include improvement or worsening of the disease, the individual patient's response to the medicine, and the effects on the patient of exposure to stressful circumstances unrelated to the symptoms of the disease being treated. In the latter situation, it may be necessary to increase the dose for a period appropriate to the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the medicine. 2. Multiple sclerosis For treatment of acute exacerbations of multiple sclerosis, it is effective to administer prednisolone 200mg daily for 1 week, followed by prednisolone 80mg every other day for 1 month (4mg of methylprednisolone is equivalent to 5mg of prednisolone). 3. ADT (Alternate Day Therapy) Alternate-day therapy is a regimen in which twice the daily dose is administered on one morning every other day. Although a single morning dose results in substantially less adrenal suppression than taking prednisolone (10mg) in 4 divided doses every 6 hours, there is evidence that when pharmacologic doses are used, a slight suppressive effect on adrenal activity continues into the following day. 3) ADT may be used initially for less severe diseases for which corticosteroid therapy is indicated. In more severe disease, a regimen of high doses divided throughout the day is usually required for initial control of disease progression. The initial suppressive dose should be continued until a satisfactory clinical response is obtained, usually for 4 to 10 days in many allergic and collagen diseases. ① Switch to ADT and gradually reduce the amount of corticosteroid administered every other day. ② Reduce the daily corticosteroid dose to the minimum effective level as soon as disease progression is controlled, then switch to an alternate-day schedule. 4) Because of the benefits of ADT, this form of treatment is desirable for patients who have taken corticosteroids daily for a long period (for example, patients with rheumatoid arthritis). Since the HPA axis may already be suppressed in these patients, establishing ADT may be difficult and may not always be successful. However, regular attempts to switch are recommended. If this is difficult, administering 3 or even 4 times the daily dose every other day is preferable to merely doubling the daily dose. Once the patient's condition is controlled, attempt to reduce this dose to the lowest level. 8) If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive corticosteroid dose divided throughout the day for control. Once controlled, the established alternate-day regimen may be tried again.

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to this drug or its components, or those with infections that do not have effective antibacterial agents, including systemic fungal infections, as this could worsen the infection. Additionally, it should not be used in patients with herpes simplex, shingles, chickenpox, or those receiving live vaccines. It should also not be administered to patients with hereditary lactose intolerance. There are patients who require careful administration. Patients with glaucoma, tuberculous diseases, subcapsular cataracts, electrolyte abnormalities, hypertension, thrombosis, recent surgeries, a history of acute myocardial infarction, peptic ulcer, psychosis, severe osteoporosis, and other various conditions should exercise special caution when using this drug. This drug suppresses immune function, so it should be used cautiously in patients with infections, diabetes, renal failure, congestive heart failure, hypothyroidism, fatty liver, the elderly, etc. Side effects may include edema, hypertension, muscle weakness, osteoporosis, gastrointestinal disturbances, skin changes, psychiatric symptoms, endocrine anomalies, eye diseases, and immediate consultation with healthcare professionals is required upon symptom occurrence. Long-term use may result in adrenal insufficiency, and abrupt discontinuation may cause severe withdrawal symptoms, so dosages should be gradually reduced. Care should be taken to prevent infections during the use of this drug, especially avoiding exposure to chickenpox or measles. Additionally, there may be potential interactions with various drugs, so it is essential to inform healthcare professionals if taking other medications. Pregnant or breastfeeding women should consult a doctor before use as it may affect the fetus and newborn. In children, it should be used in minimal doses and with careful observation as it may affect growth retardation. The elderly may experience side effects such as infections, diabetes, osteoporosis, and glaucoma more readily, so careful administration is required. It is very important to take this medication safely under regular check-ups and following the guidance of healthcare professionals.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral epiphysis, steroid myopathy, loss of muscle mass, pathologic fracture of the iliac bone, osteoporosis, vertebral compression fracture, arthralgia, tendon rupture, elevated ALT, elevated AST, elevated ALP, nausea, thirst, vomiting, abdominal pain, anorexia, increased appetite, peptic ulcer, abdominal distension, pancreatitis, esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, ecchymosis, suppression phenomenon of skin reactions, purpura, acne, hirsutism, hair loss, hyperpigmentation, nipple edema, increased intracranial pressure, convulsions, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth suppression in children, symptoms of latent diabetes mellitus, secondary adrenal insufficiency, pituitary non-responsiveness, decreased glucose tolerance, increased requirements for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior subcapsular cataract, secondary eye infections due to fungi or viruses, retinal disorders, exophthalmos, negative nitrogen balance due to protein catabolism, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should be maintained between 1 degree and 30 degrees Celsius at room temperature.

Appearance

White round tablet

Package unit

30 tablets/bottle, 500 tablets/bottle